European Society for Medical Oncology (ESMO)

In this video, Dr Sara Tolaney underscores the positive overall survival outcomes from the monarchE trial, reinforcing the impact of adjuvant abemaciclib plus endocrine therapy in high-risk, hormone receptor (HR)-positive/HER2-negative early breast cancer, while also noting the sustained 5-year benefits observed with ribociclib and nonsteroidal aromatase inhibitors in the NATALEE trial. Read More ›

This ASCENT-03 Phase 3 study compared sacituzumab govitecan with chemotherapy in patients with previously untreated advanced TNBC who are ineligible for PD-L1 inhibitors, demonstrating potential efficacy and safety in this challenging population. Read More ›

This phase 1/2 trial presents the first clinical data on DB-1305/BNT325, a TROP2-targeting antibody–drug conjugate, demonstrating efficacy and safety in patients with pretreated triple-negative breast cancer. Read More ›

The phase 3 ASCENT-04/KEYNOTE-D19 trial evaluated patient-reported outcomes comparing sacituzumab govitecan plus pembrolizumab with chemotherapy plus pembrolizumab in previously untreated PD-L1–positive metastatic TNBC, offering insights into quality of life and symptom management. Read More ›

This trial evaluated the addition of low-dose pembrolizumab to neoadjuvant anthracycline and taxane regimens, revealing potential synergy in triple-negative breast cancer. Read More ›

This study highlights the remarkable antitumor potency of a novel MUC1-C ADC, offering a promising therapeutic option for patients with triple-negative breast cancer. Read More ›

Real-world data from Finland highlight the persistent risk of recurrence in hormone receptor (HR)-positive/HER2-negative early breast cancer (EBC) patients meeting NATALEE and monarchE criteria, underscoring the need for improved treatment strategies beyond standard care. Read More ›

The SERENA-6 trial evaluates patient-reported outcomes for camizestrant combined with cyclin-dependent kinase (CDK)4/6 inhibitors in hormone receptor (HR)-positive/HER2-negative advanced breast cancer patients with emergent ESR1 mutations during first-line endocrine therapy. Read More ›

This study highlights nursing care improvements for oral mucositis in TROP2 antibody−drug conjugate (ADC)-treated patients, prioritizing prevention, patient education, and seamless dental care integration. Read More ›

The ELEANOR study explores extended adjuvant neratinib in HER2-positive/hormone receptor (HR)-positive early breast cancer, providing critical insights from clinical routine across multiple countries. Read More ›